C.F.R. » Title 17 » CHAPTER II—SECURITIES AND EXCHANGE COMMISSION › PART 229—STANDARD INSTRUCTIONS FOR FILING FORMS UNDER SECURITIES ACT OF 1933, SECURITIES EXCHANGE ACT OF 1934 AND ENERGY POLICY AND CONSERVATION ACT OF 1975—REGULATION S-K › Subpart 229.300—Financial Information

17 C.F.R. § 229.307

(Item 307) Disclosure controls and procedures

Read at: eCFRecfr.gov CornellLII GovInfogovinfo.gov CasesGoogle Scholar

Disclose the conclusions of the registrant's principal executive and principal financial officers, or persons performing similar functions, regarding the effectiveness of the registrant's disclosure controls and procedures (as defined in § 240.13a-15(e) or § 240.15d-15(e) of this chapter) as of the end of the period covered by the report, based on the evaluation of these controls and procedures required by paragraph (b) of § 240.13a-15 or § 240.15d-15 of this chapter.

[68 FR 36663, June 18, 2003]
Notes of Decisions
Cited in 2 cases, 2020–2020 · leading case: Holwill v. AbbVie Inc., No. 1:18-cv-06790, 2020 WL 5235005 (N.D. Ill. Sept. 1, 2020).
Sort: Relevance Newest Treatment
Holwill v. AbbVie Inc., No. 1:18-cv-06790, 2020 WL 5235005 (N.D. Ill. Sept. 1, 2020). “And on Item 307, which requires certain officers to present conclusions about the effectiveness of internal controls and procedures, 17 C.F.R. § 229.307 , the Court agrees with Plaintiff that Gonzalez and Chase could not have truthfully certified that AbbVie’s disclosure…”
Walker v. L Brands, Inc., No. 2:19-cv-03186 (S.D. Ohio Oct. 16, 2020). “17 C.F.R. § 229.307 . As the Court just discussed, Plaintiff fails to identify any material omissions committed by Defendants in the MD&A of the relevant Form 10-Qs.”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.